KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Revenue (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Revenue data on record, last reported at $44.6 million in Q4 2025.

  • For Q4 2025, Revenue rose 13.82% year-over-year to $44.6 million; the TTM value through Dec 2025 reached $160.0 million, up 3.89%, while the annual FY2025 figure was $160.0 million, 3.89% up from the prior year.
  • Revenue reached $44.6 million in Q4 2025 per PACB's latest filing, up from $38.4 million in the prior quarter.
  • Across five years, Revenue topped out at $58.4 million in Q4 2023 and bottomed at $27.4 million in Q4 2022.
  • Average Revenue over 5 years is $38.7 million, with a median of $37.8 million recorded in 2025.
  • Peak YoY movement for Revenue: soared 113.35% in 2023, then crashed 32.79% in 2024.
  • A 5-year view of Revenue shows it stood at $36.0 million in 2021, then dropped by 24.06% to $27.4 million in 2022, then surged by 113.35% to $58.4 million in 2023, then plummeted by 32.79% to $39.2 million in 2024, then rose by 13.82% to $44.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $44.6 million in Q4 2025, $38.4 million in Q3 2025, and $39.8 million in Q2 2025.